S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
Log in
NASDAQ:NXTC

NextCure Stock Forecast, Price & News

$12.60
-0.37 (-2.85 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.24
Now: $12.60
$13.08
50-Day Range
$10.36
MA: $11.37
$13.07
52-Week Range
$7.91
Now: $12.60
$50.76
Volume178,791 shs
Average Volume312,339 shs
Market Capitalization$347.17 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.4
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.

MarketRank

Overall MarketRank

1.60 out of 5 stars

Medical Sector

302nd out of 1,926 stocks

Pharmaceutical Preparations Industry

155th out of 773 stocks

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
CUSIPN/A
CIKN/A
Phone240-399-4900
Employees69

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.35 million
Book Value$14.13 per share

Profitability

Net Income$-33,740,000.00

Miscellaneous

Market Cap$347.17 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$12.60
-0.37 (-2.85 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NextCure (NASDAQ:NXTC) Frequently Asked Questions

How has NextCure's stock price been impacted by Coronavirus?

NextCure's stock was trading at $38.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NXTC stock has decreased by 67.0% and is now trading at $12.60.
View which stocks have been most impacted by COVID-19
.

Is NextCure a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NextCure stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NXTC, but not buy additional shares or sell existing shares.
View analyst ratings for NextCure
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than NextCure?

Wall Street analysts have given NextCure a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NextCure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as NextCure's CEO?

1,448 employees have rated NextCure CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among NextCure's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is NextCure's next earnings date?

NextCure is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for NextCure
.

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) issued its quarterly earnings results on Thursday, November, 5th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.02.
View NextCure's earnings history
.

What price target have analysts set for NXTC?

8 equities research analysts have issued twelve-month price objectives for NextCure's stock. Their forecasts range from $10.00 to $55.00. On average, they expect NextCure's share price to reach $23.33 in the next year. This suggests a possible upside of 85.2% from the stock's current price.
View analysts' price targets for NextCure
or view Wall Street analyst' top-rated stocks.

Are investors shorting NextCure?

NextCure saw a decline in short interest in December. As of December 31st, there was short interest totaling 1,120,000 shares, a decline of 32.1% from the December 15th total of 1,650,000 shares. Based on an average daily trading volume, of 433,100 shares, the short-interest ratio is currently 2.6 days. Currently, 6.5% of the shares of the stock are sold short.
View NextCure's Short Interest
.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), OrganiGram (OGI), (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

Who are NextCure's key executives?

NextCure's management team includes the following people:
  • Mr. Michael S. Richman, Co-Founder, CEO, Pres & Director (Age 60, Pay $625.68k)
  • Dr. Solomon Langermann, Chief Scientific Officer (Age 62, Pay $459.11k)
  • Dr. Lieping Chen M.D., Ph.D., Co-Founder & Chairman of Scientific Advisory Board (Age 64)
  • Mr. Steven P. Cobourn CPA, CPA, Chief Financial Officer (Age 58)
  • Dr. Timothy Mayer Ph.D., Chief Operating Officer (Age 57)
  • Dr. Linda N. Liu, Sr. VP of Research (Age 55)
  • Dr. James B. Bingham Ph.D., Chief Devel. Officer (Age 55)

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $12.60.

How big of a company is NextCure?

NextCure has a market capitalization of $347.17 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. NextCure employs 69 workers across the globe.

What is NextCure's official website?

The official website for NextCure is www.nextcure.com.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.